Search

Search Results

• IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Alana Kennedy-Nasser, Catherine Bollard, Helen Heslop

  e2009010

  2009-11-13

  https://doi.org/10.4084/mjhid.2009.010

  1141

  PDF: 592

  HTML: 6788

• MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS

  Elena Maino, Anna Maria Scattolin, Piera Viero, Rosaria Sancetta, Anna Pascarella, Michele Vespignani, Renato Bassan

  e2015001

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.001

  2248

  PDF: 1310

  HTML: 17067

  Bassan Fig.1: 135

  Bassan Fig.2: 139

  Bassan Fig.4: 129

  Fig.3: 172

• CUPROPTOSIS: A REVIEW ON MECHANISMS, ROLE IN SOLID AND HEMATOLOGICAL TUMORS, AND ASSOCIATION WITH VIRAL INFECTIONS

  MAURIZIO MARTINI, Pietro Tralongo, Mariagiovanna Ballato, Vincenzo Fiorentino, Walter Giordano, Valeria zuccalà, Cristina Pizzimenti, Arianna Bakacs, Antonio Ieni, Giovanni Tuccari, Guido Fadda, Luigi Maria Larocca

  e2025052

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.052

  1610

  PDF: 933

  HTML: 174

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1504

  PDF: 1173

  HTML: 173

• INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB

  Wonhee So, Shuchi Pandya, Rod Quilitz, John Greene

  e2018029

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.029

  2768

  PDF: 1017

  HTML: 294

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1475

  PDF: 912

  HTML: 214

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2034

  PDF: 1631

  HTML: 351

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  1976

  PDF: 744

  HTML: 3104

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1675

  PDF: 819

  HTML: 139

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4737

  PDF: 1733

  HTML: 2692

  Untitled: 199

• Cauda equina enhancing lesion in a HIV-positive patient. Case report and literature revision.

  Pasquale De Bonis, Antonella Cingolani, Angelo Pompucci, Tommaso Tartaglione, Luigi Maria Larocca, Luciana Teofili

  e2011042

  2011-10-02

  https://doi.org/10.4084/mjhid.2011.042

  1791

  PDF: 822

  HTML: 740

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2032

  PDF: 1487

  HTML: 264

• LUMBAR PUNCTURE: A CROSS-SECTIONAL STUDY USING THE CHINESE VERSION OF THE STATE ANXIETY SCALE FOR CHILDREN.

  Xiuli Qin, Xin Zhao, Ting Zhou, Danyan Yang, Genzhen Yu

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.021

  522

  PDF: 341

  HTML: 69

• Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure

  SUPARNO CHAKRABARTI

  e2020047

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.047

  1114

  PDF: 892

  HTML: 282

• Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin

  Caterina Giovanna Valentini, Valentina Bozzoli, Anna Rita Larici, Luigi Maria Larocca, Giovanni Delogu, Giuseppe Leone, Livio Pagano

  e2012040

  2012-06-18

  https://doi.org/10.4084/mjhid.2012.040

  1829

  PDF: 626

  HTML: 19234

• IMMUNITY TO INFECTIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Franco Aversa, Lucia Prezioso, Ilenia Manfra, Federica Galaverna, Angelica Spolzino, Alessandro Monti

  e2016057

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.057

  4275

  PDF: 1080

  HTML: 1402

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1255

  PDF: 722

  HTML: 1391

• THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA

  Yingying Li, Yang Li, Wenguo Cheng

  e2025073

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.073

  444

  PDF: 232

  HTML: 75

• TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Marta Muzio, Eleonora Fonte, Federico Caligaris-Cappio

  e2012055

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.055

  2539

  PDF: 850

  HTML: 17457

  Fig1 Caligaris: 154

  Fig.2 Caliga: 187

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1646

  PDF: 1625

  HTML: 772

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1571

  PDF: 1066

  HTML: 106

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2132

  PDF: 1970

  HTML: 159

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4271

  PDF: 1466

  HTML: 1536

  Untitled: 212

• APLASTIC ANEMIA AND VIRAL HEPATITIS

  Laura Cudillo

  e2009026

  https://doi.org/10.4084/mjhid.2009.026

  1233

  PDF: 518

  HTML: 23019

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  2029

  PDF: 1418

  HTML: 256

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  3923

  PDF: 3227

  HTML: 190

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4007

  PDF: 1124

  HTML: 1923

  Fig.1: 209

  Fig. 2: 104

  Table 1: 192

  Table2: 206

  Table 3: 186

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1475

  PDF: 1309

  HTML: 108

• REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Giovanni D'arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio

  e2012053

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.053

  2282

  PDF: 955

  HTML: 7608

  Untitled: 261

  Fig2: 172

  Fig3: 155

  Fig4: 169

• Is laboratory monitoring useful in DOACs management?

  Mario Biglietto, Rosaria Mormile, Matteo Totaro, Maria Laura Bisegna, Cristina Santoro, Antonio Chistolini

  e2025019

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.019

  804

  PDF: 785

  HTML: 101

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1121

  PDF: 929

  HTML: 130

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1523

  PDF: 584

  HTML: 175

• Hemophagocytic lymphohistiocytosis: an unusual complication in Orientia tsutsugamushi disease (scrub typhus).

  Aneesh Basheer, Somanath Padhi, Vinoth Boopathy, Saumyaranjan Mallick, Shashikala Nair, Renu G'Boy Varghese, Reba Kanungo

  e2015008

  2014-12-23

  https://doi.org/10.4084/mjhid.2015.008

  3987

  PDF: 1518

  HTML: 4328

• MOLECULAR MECHANISM OF TRAF6 IN MALIGNANT PROLIFERATION OF HUMAN NK/T CELL LYMPHOMA CELL HANK1

  Yan Qi, Chengbo Xu, Zesong Chen, Jiawei Chen, Congjie Chen

  e2025074

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.074

  450

  PDF: 199

  html: 30

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2198

  PDF: 1769

  HTML: 132

• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

  Maria L. Delioukina, Stephen J. Forman

  e2010018

  2010-06-30

  https://doi.org/10.4084/mjhid.2010.018

  1211

  PDF: 774

  HTML: 527

• ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Angelo Michele Carella

  e2012059

  2012-10-02

  https://doi.org/10.4084/mjhid.2012.059

  1987

  PDF: 781

  HTML: 1030

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1261

  HTML: 290

  PDF: 915

  Suppl. Files: 437

• PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma

  Ugo Testa; Giuseppe G.M. Leone

  e2025005

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.005

  2404

  HTML: 259

  PDF: 848

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1363

  PDF: 648

  HTML: 1499

• COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.

  Federico Mercolini, Simone Cesaro

  e2022009

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.009

  2179

  PDF: 920

  HTML: 286

• IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE

  Francesco Di Raimondo, Giorgio La Nasa

  e2014039

  2014-05-29

  https://doi.org/10.4084/mjhid.2014.039

  2188

  PDF: 938

  HTML: 1879

• Achieving the cure of follicular lymphoma: is it time to finalize treatment strategies to reach this goal in a subset of patients?

  Mauro Passucci, Giovanni Assanto, Alessandro Pulsoni

  e2023018

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.018

  1098

  PDF: 889

  HTML: 337

• EPSTEIN-BARR VIRUS RELATED LYMPHOPROLIFERATIONS AFTER STEM CELL TRANSPLANTATION

  Simona Sica, Elisabetta Metafuni, Silvia Bellesi, Patrizia Chiusolo

  e2009019

  2009-12-14

  https://doi.org/10.4084/mjhid.2009.019

  1279

  PDF: 552

  HTML: 2974

• THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti

  e2013027

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.027

  2098

  PDF: 1013

  HTML: 2701

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4254

  PDF: 1718

  HTML: 1098

• FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator

  Claudio Ucciferri, Francesca Chiappini, Jacopo Vecchiet, Katia Falasca

  e2025057

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.057

  2216

  PDF: 886

  HTML: 353

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  2842

  PDF: 862

  HTML: 1388

• COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

  Jean Elcheikh

  e2015048

  2015-08-21

  https://doi.org/10.4084/mjhid.2015.048

  1860

  PDF: 990

  HTML: 1326

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1628

  PDF: 584

  HTML: 13924